Optimal tumor cell surface expression of human leukocyte antigen (HLA) class I molecules is essential for the presentation of tumorassociated peptides to T-lymphocytes. However, a hallmark of many types of tumor is the loss or downregulation of HLA class I expression associated with ineffective tumor antigen presentation to T cells. Frequently, HLA loss can be caused by structural alterations in genes coding for HLA class I complex, including the light chain of the complex, b2-microglobulin (b2m). Its bestcharacterized function is to interact with HLA heavy chain and stabilize the complex leading to a formation of antigen-binding cleft recognized by T-cell receptor on CD8 þ T cells. Our previous study demonstrated that alterations in the b2m gene are frequently associated with cancer immune escape leading to metastatic progression and resistance to immunotherapy. These types of defects require genetic transfer strategies to recover normal expression of HLA genes. Here we characterize a replication-deficient adenoviral vector carrying human b2m gene, which is efficient in recovering proper tumor cell surface HLA class I expression in b2m-negative tumor cells without compromising the antigen presentation machinery. Tumor cells transduced with b2m induced strong activation of T cells in a peptide-specific HLA-restricted manner. Gene therapy using recombinant adenoviral vectors encoding HLA genes increases tumor antigen presentation and represents a powerful tool for modulation of tumor cell immunogenicity by restoration of missing or altered HLA genes. It should be considered as part of cancer treatment in combination with immunotherapy.
INTRODUCTION
Various mechanisms contribute to the failure of the immune control of tumor growth and enable malignant tumors to evade immune surveillance; 1 hence, currently there is a great effort to develop effective vaccination therapies in order to boost the T-cell response and induce tumor regression in cancer patients. 2 Cytotoxic T lymphocytes (CTL) directed against tumor-associated peptides presented by human leukocyte antigen (HLA)-class-I complex consisting of a heavy chain and b2-microglobulin (b2m) as a light chain constitute powerful effectors of the immune system against tumors. However, tumor cells often lose HLA class I antigens limiting the efficacy of cancer immunotherapy aimed at activation of the immune system to recognize malignant cells and initiate tumor rejection. Impaired tumor HLA class I expression can be due to alterations at any stage of HLA class I component production, assembly or transport to the cell surface. The expression of HLA class I molecules at the cell surface depends upon the appropriate assembly of three major components, a heavy chain, b2m and a peptide in the endoplasmic reticulum (ER). The antigenic peptide epitopes are generated in the cytosol by degradation of endogenously synthesized protein, primarily by the proteasome complex. The generated peptides are transported from the cytosol into the ER by the ATP-dependent transporter associated with antigen processing (TAP). Within the ER, peptides are further trimmed by aminopeptidases. The binding of peptides by class I molecules is thought to occur within a multimolecular compound termed the peptide loading complex, which consists of a TAP heterodimer, tapasin, calreticulin, calnexin and ERp57. While the chaperone calreticulin and the thiol-oxidoreductase ERp57 promote appropriate folding and disulphide bond formation, tapasin promotes the stabilization of the peptide loading complex and aids in the appropriate selection of peptides. Following peptide binding, HLA-peptide complexes are released from the peptide loading complex and shuttled via the Golgi apparatus to the cell surface where they are recognized by CTLs, which triggers an immune response. 3, 4 The expression of many of the components of the antigen presentation machinery (APM) is inducible by interferon (IFN)-g. Therefore, upregulation of the tumor HLA class I expression as a result of immunostimulation by IFN-g is, at least partially, responsible for the clinical efficacy of cancer immunotherapy. However, if the molecular alteration underlying HLA loss is irreversible and caused by genetic defects in genes coding for class I molecules, the immunotherapy may fail. Transcriptional downregulation of HLA molecules and antigen-processing machinery (APM) components is a frequent finding in cancer. However, tumor cells harboring genetic irreversible defects easily escape immune recognition, disseminate and produce metastases resistant to immunotherapy.
The loss of b2m can be caused by structural irreversible alterations in the corresponding gene, loss of heterozygocity (LOH) of chromosome 15 (LOH-15) causing loss of one copy of b2m gene, and mutation/deletion in the other copy of b2m gene. The frequency of b2m loss by LOH-15 in primary tumors vary: 44% of bladder carcinoma, 41% of laryngeal carcinoma, 35% of colorectal carcinoma, 29% of sporadic breast cancer, 12% of breast cancer, 16% of melanoma and 7% of studied renal cell carcinoma 5, 6 lose a copy of b2m gene via LOH. Different b2m gene mutations have been recently reviewed in our group 6 and was reported in 29% of diffuse large B-cell lymphomas, 7 in colon carcinoma (21%) and melanoma (15%), and to a less extent in other types of cancer (o5%).
Our recent studies show that the resistance to immunotherapy and generation of progressing metastases seems to be correlated with HLA class I altered expression and is a consequence of immune escape and dissemination of HLA-negative tumor cells. Recently, we reported that progressing metastases or recurrent tumors after immunotherapy have increased percentage of HLA class I alterations with profound structural defects in HLA genes. 8, 9 Therefore, recovery of normal tumor HLA class I expression in patients with local cancer relapse or metastatic progression with underlying genetic defects becomes essential. This approach has been used previously in in vitro studies to demonstrate the importance of HLA class I molecules in specific tumor lysis by CTL and natural killer cells, 10, 11 although without using adenoviral vectors. For transient transduction of target cells, adenoviral vector systems possess the highest efficacy 12 and they have been used in 23% of the registered clinical trials of gene therapy for different indications, including for boosting anticancer immunity. 13, 14 These vectors have several biologic characteristics, which make them effective for cancer gene therapy: a broad host/cell range, high levels of transgene expression and episomal localization with almost no integration into tumor cell genome, which prevents increasing genetic instability and activation of oncogene expression. In addition, adenoviral vectors can be produced in large titers (up to 10 12 p.f.u. ml -1 ) with amounts sufficient for clinical use. However, some components of the HLA class I assembly pathway have been found to be inhibited by numerous viral proteins 15, 16 in a virus counterattack strategy against the cellular immune response with the goal of freely replicate in infected cells. Adenoviruses are able to specifically downregulate the cell surface expression of HLA class I antigens 17 via two distinct mechanisms both involving a gene product of the E3 region, the E3/19K protein. The adenoviral protein E3/19K binds 18, 19 and downregulates cell surface HLA class I expression by direct retention of HLA heavy chain in the ER [20] [21] [22] through an ER retention signal that contributes to intracellular sequestration of HLA class I molecules. 23 At the same time E3/19K also binds to TAP, resulting in the blockage of the association of TAP with tapasin, preventing class I/TAP association. 24, 25 Furthermore, viral proteins have been also reported to modulate (either positively or negatively, either in a direct or indirect manner) the apoptotic response of host cells to infection. Although we are using an adenoviral vector lacking the E1 and E3 regions, we cannot exclude the existence of other targets for virus-mediated inhibition of HLA expression, which has not been sufficiently investigated yet or the effect is due to the presence of traces of replication competent adenovirus in a recombinant adenovirus preparation. We also analyzed how transduction with adenoviral vector carrying b2m gene influences tumor cell proliferation and apoptosis. We have constructed a replication-deficient adenoviral vector carrying human b2m gene and demonstrated its effectiveness in restoration of HLA class I expression both in vitro, in various types of b2m-negative human tumor cells, and in vivo, in human tumor xenograft transplants. 26 Here, we further characterize the vector and confirm the functional restoration of the HLA class I complex by analyzing the ability to induce tumor antigen-specific activation of CTLs. Furthermore, for cancer gene therapy application it is critical to ensure that APM is not inhibited by the viral vectors used to increase tumor immunogenicity and upregulates HLA class I expression. We examined how the b2m coding adenoviral vector influences APM components, tumor cell proliferation and apoptosis.
MATERIALS AND METHODS

Cells lines and antibodies
Human cancer cell lines, including melanoma (ESTDAB-109, ESTDAB-038, MaMel-86b, MaMel-128b and DNR-DC-M010), colorectal adenocarcinoma DLD-1, Burkitt lymphoma cell line Daudi and prostate cancer cell line OPCN-3 were previously described. 26 All these cell lines have total loss of HLA class I expression caused by structural defects in both copies of b2m gene. ESTDAB-007, ESTDAB-038 and ESTDAB-109 melanoma cell lines were obtained from the European Searchable Tumor Cell Line Data Base (ESTDAB project, contract no.QLRI-CT-2001-01325). 27 MaMel-86b and MaMel-128 were kindly provided by Dr Annette Paschen (University Hospital Essen, Essen, Germany) and DNR-DC-M010 melanoma cell line (received as part of European collaborative project ENACT) kindly provided by Dr Gustav Gaudernack and Dr Amund Kyte (University of Oslo Medical School, Oslo, Norway). HLA-I-positive prostate cancer cell lines PC-3 and DU-145 were purchased from ATCC (LGC Standards S.L.U., Barcelona, Spain). HLA class I expression was studied with the following monoclonal antibodies (mAbs): W6/32 (anti-HLA-ABC), L-368 (anti-b2m) previously described 26 and HC-10 (anti-HLA-BC free heavy chain). Antibodies to free HLA-A and HLA-B (rabbit mAbs against HLA-A and HLA-B (OriGene, Rockville, MD, USA). Rabbit polyclonal anti-human b2m (Abcam, Cambridge, UK) was used in some assays. APM components were studied with the following mAbs: anti-calnexin and anti-calreticulin (PIERCE, Thermo Scientific, Rockford, IL, USA), anti-tapasine, anti-ERP57, Proteasome 20S LMP-2 and LMP-7 (Abcam), and anti TAP-2 (MBL, Woburn, MA, USA), and rabbit polyclonal Ab anti-TAP-1 (Abcam). Fluorescenceactivated cell sorting (FACS) analysis of Melan-Mart-1 antigen was studied using anti-Melan A/MART-1, A103. 28 Secondary Abs: fluorescein isothiocyanate-conjugated goat anti-mouse (Sigma, St Louis, MO, USA) Ab was used for flow cytometry; horseradish peroxidase-conjugated goat anti-mouse or anti-rabbit Abs (Bio-Rad, Richmond, VA, USA) were used for immunochemistry; Alexa Fluor 488 goat anti-mouse Ab and Alexa Fluor 555 goat anti-rabbit (Invitrogen, Life Technologies, Madrid, Spain) were used for confocal analysis.
Adenoviral vectors
The construction and production of the adenoviral vector carrying human b2m gene (AdCMVb2m) and the adenoviral vector carrying GFP gene (AdCMVGFP) were previously described. 26 The empty viral vector phi5 (C5) was used as a transduction control for some cell line assays. Adenoviral infection of tumor cells Cell lines were infected at different multiplicity of infection (MOI) depending on the cell line. MOI ¼ 7 for DLD-1, ESTDAB-109, OPCN-3 and MaMel-128b; MOI ¼ 15 for ESTDAB-038, DNR-DC-M010 and Ma-Mel86b and MOI ¼ 30 for DAUDI with AdCMVb2m in a 2% fetal calf serum supplemented media, and b2m protein expression was determined 48 h after infection using flow cytometry. In some assays, cell lines were incubated for 3, 6, 12 or 24 h with AdCMVb2m and after that, culture media was replaced for a fresh media and the cells were left in culture for up to 48 h in total before testing b2m expression. To analyze a dose-dependent effect in b2m enzyme-linked immunosorbent assay (ELISA), proliferation and apoptosis assays, cell lines were infected with MOIs 8, 10, 15 or 20 times higher than the optimal dose (minimum MOI necessary to achieve maximum recovery of b2m expression measured by FACS).
Flow cytometry and immunocytochemistry Cell surface expression of HLA class I molecules was analyzed by flow cytometry as previously described. 26 Briefly, cells were incubated with primary antibodies W6/32 or L-368, washed, labeled with secondary fluorescein isothiocyanate-conjugated antibodies for 30 min at 4 1C and analyzed on BD FACS Canto flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA). For intracellular immunolabeling of HLA-A, HLA-B and LMP7 tumor cells were permeabilized using BD IntraSure kit (BD Bioscience, San Jose, CA, USA) before incubation with specific antibodies.
Immunocytochemical staining of tumor cells on glass slides (cytospin) was performed as previously described 26 using primary antibodies directed against different APM proteins, followed by incubation with horseradish peroxidase-conjugated secondary antibodies. Cells seeded in six-well plates were immunostained after 48 h of AdCMVb2m transduction. Cells were washed with phosphate-buffered saline (PBS) and fixed in ice-cold methanolacetone (1:1) for 10 min and incubated overnight with anti-b2m L-368 in blocking solution at 4 1C in a humidified chamber. After 3 Â 10-min wash with PBS-0.1% bovine serum albumin, samples were incubated with horseradish peroxidase-conjugated secondary antibody.
Confocal microscopy Cells were seeded in chamber slides (Nunc Lab-Tek Chamber Slide system, Sigma Aldrich, St Louis, MO, USA), incubated overnight and transduced with AdCMVb2m or left uninfected. Twenty-four hours later, culture media was replaced by fresh media and cells were left in culture for another 24 h. Cells were fixed in ice-cold methanol-acetone (1:1) for 10 min and incubated overnight with anti-b2m L-368, anti-b2m/heavy chain W6/32 or anti-heavy chain HC-10 mAbs in blocking solution at 4 1C in a humidified chamber. After 3 Â 10-min wash with PBS-0.1% bovine serum albumin, samples were incubated with 1:1000 Alexa Fluor 488 (green) in blocking solution for 3 h and later washed 3 Â 10-min with PBS-0.1% bovine serum albumin. Nuclear counterstaining with propidium iodide (red) was performed after removal of excess of secondary antibody and slides were mounted with fluorescence mounting media (DAKO, Agilent Technologies, Barcelona, Spain). In some experiments, two primary antibodies were used to colocalize HLA proteins with various AMP components, including calnexin, calreticulin, tapasine and ERP57; Alexa Fluor 488 (green) or Alexa Fluor 555 (red) were used as secondary antibodies. In negative control, primary antibodies were omitted in control wells. Immunostaining was visualized with a Leica Spectral confocal microscope (Leica Microsistemas S.L.U., Barcelona, Spain).
DNA and RNA isolation, reverse transcription, and quantitative real time-PCR DNA from melanoma cell lines was isolated using FlexiGene DNA Kit (Qiagen, Hilden, Germany). Primers used for Melan-Mart-1 analysis were: Fw 5 0 -CACGGCCACTCTTACACCAC-3 0 and Bw: 5 0 -GGAGCATTGGGAACCACAGG-3 0 with a predicted PCR product size of 254 bp. Total RNA was extracted from cultured tumor cells under basal conditions, stimulated by IFN-g, or transduced with C5 or AdCMVb2m using the RNeasy Mini Kit (Qiagen) and utilized for reverse-transcription-PCR using iSriptTMcDNA Synthesis Kit (Bio-Rad). The products of reverse transcription were analyzed by quantitative real-time PCR for the expression of various target genes (HLA-A, HLA-B, HLA-C, b2m, TAP-1, TAP-2, LMP-2, LMP-7 and tapasin). To control for variations in amounts of mRNA, the glucose-6-phosphate dehydrogenase and b-actin genes were amplified as well. All PCR reactions were performed in a Light Cycler instrument using the LC-FastStart DNA Master SYBR Green I Kit (Roche Diagnostics, Manheim, Germany). The primer sequences used in this study, amplicon size and annealing temperatures have been described earlier. 29 T-cell stimulation assay by measuring IFN-g secretion IFN-g was measured by ELISA in the supernatants collected after co-culturing T cells with melanoma cells either untransduced (HLA negative) or AdCMVb2m-transduced (HLA positive) cells. Peptidespecific T cells against HLA-restricted peptides MelanA/MART1 (26-35, EAAGIGILTV, HLA-A*02 restricted) were generated from peripheral blood mononuclear cell isolated from buffy coats of naive donor peripheral blood supplied by the Regional Blood Transfusion Centre of Granada. We also used autologous peripheral blood mononuclear cell for melanoma cell line DNR-DC-M010 29 received as part of European collaborative project ENACT. peripheral blood mononuclear cells were isolated by density gradient centrifugation on Histopaque and incubated overnight in tissue culture flasks at 37 1C to separate adherent from nonadherent T-cell-enriched cells (purity of CD3 þ was higher than 85%). Adherent cells were further stimulated with 2 ng ml -1 IL-4 (R&D Systems, Minneapolis, MN, USA), and 3 ng ml -1 of granulocyte-macrophage colony-stimulating factor (R&D Systems) for induction of DC for further priming of T cells. T cells were expanded by stimulation with 1 mg ml -1 of IL-2 (Proleukin, Novartis Pharmaceuticals, Basel, Switzerland) and 10 ng ml -1 of IL-7 (R&D Systems) and pulsed two to three times (5-7 days apart) with either irradiated DCs or with irradiated HLA-A*0201-matched HLApositive tumor cells ESTDAB-007 (stimulating cells) in the presence of MelanA/Mart1 peptide (1 mg ml -1 ). After that, the peptide-specific responder T cells were washed and seeded into 96-well plates with tumor cells alone in a ratio of (10:1) in the presence or absence of a corresponding peptide. T-cell stimulation was measured as IFN-g release (pg ml b2m ELISA and proliferation assay The levels of secreted b2m in culture supernatants after AdCMVb2m transduction were determined by a commercial Human b-2 Microglobulin ELISA Kit (Alpha Diagnostic International, San Antonio, TX, USA). Briefly, cells were cultured with media alone or infected with AdCMVb2m at previously described MOIs. Culture supernatants were collected 48 h later and the amount of b2m protein was determined according to the manufacturer's protocol. The methylthiazol tetrazolium (MTT) assay was used to measure the impact of b2m-rich supernatants from transduced tumor cells (melanoma and prostate cancer) and of purified b2m from human urine (Sigma Aldrich) on the proliferation of prostate cancer cells PC-3 and DU-145. Briefly, tumor cells were plated into 96-well plates in culture medium containing 5% fetal bovine serum. After 24 h of incubation, the media was replaced by the supernatants of AdCMVb2m-infected or C5-infected tumor cells and left in culture for 72 h. After the incubation period, the assay was performed according to the manufacturer's manual and the absorbance of formazan-containing cell culture medium was measured in each well using a ELISA microplate reader (at A570 nm) (Biotek, Power-Wave XS, Winooski, VT, USA).
Analysis of apoptosis: PE-AnnexinV/7-AAD staining FACS analysis with Annexin-V (phycoerythrin (PE)-Annexin-V) and 7-amino-actinomycin D (7-AAD) staining was used for the determination of cell apoptosis following transduction with AdCMVb2m or with control virus C5 at optimal MOI or MOI 8 and 15 times higher (PE-Annexin-V-positive: early apoptosis; 7-AAD: late apoptosis/necrotic) following the manufacturer's protocol (PE Annexin V Apoptosis Detection Kit, BD Biosciences). Briefly, cells were washed twice in PBS and suspended in Annexinbinding buffer. Staining mixture of 5 ml PE-Annexin-V and 5 ml 7-AAD was added to 100 ml of cell suspension (10 6 cells ml -1 ). Cells were incubated in the dark for 15 min at room temperature and then analyzed on BD FACS Canto flow cytometer. Viable cells are negative for 7-AAD and PE-Annexin-V labeling; early apoptotic cells are only positive for Annexin-V labeling; late apoptotic cells are positive for both Annexin-V and 7-AAD positive. Anti-b2m antibody L368 with fluorescein isothiocyanate-labeled secondary Ab was used to confirm the recovery of b2m expression after viral transduction in FACS assay.
Statistical analysis
Fisher's exact test was used to analyze the data. Statistical significance was established at Po0.05. The statistical analysis was performed using SPSS 10.0 software (SPSS, Chicago, IL, USA).
RESULTS
We have previously described that adenoviral vector coding for human b2m gene (AdCMVb2m) was able to successfully recover HLA class I expression in tumor cells in vitro and in vivo. 26 In these experiments, we used human tumor cell lines of distinct histological type, all with a total HLA class I loss because of the lack of b2m protein caused by alterations in the corresponding gene. Here we further characterize the vector-mediated transgene expression, describe how the virus affects tumor APM, and how it influences the proliferation and apoptosis of cancer cells. and 24 h); after that the culture media was replaced for a virus-free one and the recovery of b2m expression was confirmed by fluorescence-activated cell sorting (FACS) using L-368 monoclonal antibody (mAb) after 48 h of incubation in total. Three hours after infection, the expression of b2m was already positive (middle histogram), reaching its maximum 12 h after infection and remained unchanged at 24 h after viral transduction (lower histogram).
the heavy chain molecules (HC-10 mAb, green) and polyclonal anti-b2m protein (red) was found as expected in the Golgi area of the cytoplasm of transduced cells (Figure 2c , left images). Double staining with W6/32 mAb (green) and b2m recombinant protein (red) (Figure 2c , right images) indirectly confirmed the expected proper assembly with the heavy chain assisted by APM molecules, ER localization and transport to the cell surface.
Impact of the adenovirus-mediated b2m recovery on the transcriptional expression levels of HLA-A, B-, C-loci It is also important to examine how adenovirus-mediated upregulation of b2m expression affects tumor HLA heavy chain locus expression, as different tumor-specific peptides have different binding affinity and antigen presentation specificity via various HLA-ABC loci. We measured the transcriptional levels of the , and anti-free-heavy chain antibody HC-10 (green). Propidium iodate was used for nuclear labeling (red). (c) In some experiments, a colocalization of b2m transgene with the heavy chain was analyzed by merging the images of b2m immunolabeling with polyclonal antibody (red), and monoclonal antibodies (mAbs) to heavy chain (HC-10) and class I complex (W6/32) (both green).
HLA-A, B or C loci by quantitative PCR in melanoma cells DNR-DC-M010 and ESTDAB-109 3 days after infection with the adenovirus (Figure 3) . In control experiments, cells were transduced with C5 or incubated 48 h with IFN-g to upregulate the expression of the loci. Figure 3a shows that both C5 and AdCMVb2m increase locus B transcription in the studied melanoma cell lines. Locus C expression remains unaltered in DNR-DC-M010 cells, but is higher in ESTDAB-109 cells after infection. HLA-A transcription is lower in DNR-DC-M010 cells transfected with AdCMVb2m, but not with C5, while in ESTDAB-109 cells locus A expression remained unchanged independently on the type of the virus used for infection. We also analyzed intracellular protein expression of HLA-A and B loci (unfortunately we did not have good anti-locus C mAb for this assay) in the studied permeabilized tumor cells in basal condition and after viral transduction with AdCMVb2m or c5. The absence of b2m protein makes impossible the intracellular assembly of the HLA class I complex and its transport to the cell surface. Therefore, HLA heavy chain can be detected only in the cytoplasm; hence, we permeabilized cells before immunolabeling. The results of these experiments shown in Figure 3b show that but not C5 increases b2m transcription. Also IFN-g increases the transcription as expected as the defect in b2m in the cell lines is at translational level. Infection with C5 and AdCMVb2m decreases transcription of LMP2, LMP7, TAP1 and TAP2, and increases the level of tapasin. However, we observed different patterns of APM changes in six tumor cell lines (five melanomas and one colon adenocarcinoma) in response to the infection with adenovirus. Figure 4b shows an example of the AdCMVb2m-induced modulation of LMP-7 expression in different tumor cell lines, which has a different pattern depending on cell type. In some cells, like DNR-DC-M010, viral transduction reduced transcription of LMP-7, while in cell lines ESTDAB-109 and MaMel86b virus increased this transcriptional expression. However, when we examined LMP-7 expression in Mamel86b and ESTDAB-109 cells before and after AdCMVb2m transduction by immunocytochemistry (Figure 4c ), we did not see any difference in the intensity of immunolabeling. Similarly, FACS analysis on permeabilized DNR-DC-M010 and ESTDAB-109 cells (Figure 4d ) did not show any marked difference in the LMP-7 expression intensity despite the previously observed difference at transcriptional level (Figure 4b ).
ESTDAB-109
In addition, we analyzed by confocal immunofluorescence microscopy the cellular colocalization of the newly produced b2m and several molecules of the APM complex, including tapasin, calnexin, calreticulin and ERp57. Figure 5 depicts a colocalization of the newly synthesized b2m protein with each of the studied APM molecules in the epinuclear area within the ER. These results showed that adenovirus-mediated modification of APM transcription varies among the studied tumor cell lines. Although in some cases, transduced cells show transcriptional downregulation in some APM molecules, it does not affect the protein expression allowing a proper interaction with b2m and HLA class I heavy chain, and correct transport from ER to the cell surface via Golgi apparatus.
Functional activity of re-expressed HLA class I complex To confirm that the restoration of HLA class I expression on b2m-negative cells was able to induce cellular immune responses mediated by CTLs, we tested the ability of AdCMVb2m-transduced DNR-DC-M010 melanoma cells to induce IFN-g secretion by MelanA/MART-1-specific HLA-matched T cells. Melanoma cell lines DNR-DC-M010 (does not express HLA class I because of a mutation in b2m gene) 29 and ESTDAB-007 (HLA-A*0201-positive) were used in these assays. First, using PCR and FACS analysis with A103 antibody we confirmed that both cells lines express melanoma peptide MelanA/MART-1 (Figures 6a and b) . HLA-matched Melan/ Mart-1-specific T cells were obtained after co-culturing MelanA/ Mart-1-pulsed-DCs as feeder cells and DNR-DC-M010 cells infected with AdCMVb2m or with control adenovirus C5 and 48 h later IFNg in collected supernatants was measured by ELISA. As shown in Figure 6c , IFN-g production was detected at a significantly higher level (fourfold) in the supernatants when target cells were transduced with AdCMVb2m in the presence of MelanA/Mart-1 peptide, as opposed to the same target without the addition of Measurement of secreted b2m protein in the supernatants of AdCMVb2m-transduced cells and its effect on tumor cell proliferation We have demonstrated above that b2m protein produced by adenovirus-mediated gene transfer is properly expressed on tumor cell surface in a complex with HLA heavy chain. However, it is expected that in case of b2m overproduction the excess of the newly synthesized b2m will not have enough free heavy chains to form HLA class I complex with peptides and will be secreted into the extracellular space. Elevated level of soluble b2m in the serum and urine of patients with autoimmune and malignant diseases has been frequently reported. 30, 31 In addition, there are few reports suggesting that b2m can promote proliferation of prostate cancer cells. 32 We wanted to test whether in our experiments the newly expressed b2m protein sheds off the cell surface and potentially can increase tumor cell proliferation. We analyzed the level of b2m protein in the supernatants of melanoma cells transduced with AdCMVb2m and used these samples to incubate with non-transduced prostate HLA-positive cancer cells. After 72 h of incubation, cell proliferation was measured by MTT test and by direct counting of the number of Trypan blue-negative cells using a hemocytometer. First, we measured the b2m protein levels in culture media from different cell lines after 72 h of transduction with AdCMVb2m at their correspondent MOIs. 26 As it is shown in Figure 7a , the b2m protein level as determined by ELISA at basal conditions was undetectable (as expected because of the lack of b2m protein in the cells). After adenoviral transduction, there was an increase in b2m protein level reaching levels ranging from 50 to 200 ng ml -1 depending on cell line. In all the five studied melanoma cell lines, the b2m protein secretion level was above 100 ng ml -1 , reaching the maximum level of 200 ng ml -1 in the supernatants of transduced ESTAB-109, DNR-DC-M010 and MaMel-128b cells. Comparable numbers were obtained for colorectal adenocarcinoma DLD-1 and for the Burkitt lymphoma DAUDI, although this last one did not recover cell surface b2m expression, but secreted soluble b2m protein. Prostate cell line OPCN-3 showed a minimal production of secreted b2m protein. The concentration of the secreted soluble b2m protein was dose dependent (Figure 7b ). Under these conditions, a tenfold increase of MOI augmented secretion of b2m up to 1 mg ml -1 , while infection with 20 fold MOI increased this concentration to 2 mg ml -1 (for ESTDAB-109 cell line). The dose-dependent effect of secreted b2m on cell proliferation was examined in cultured prostate cell lines DU-145 and PC-3 using MTT assay. As shown in Figure 8a , the addition of supernatants from transduced melanoma cells (with different MOI) did not change the proliferation rate of prostate cell lines, although a slight decrease in DU-145 proliferation was observed ( Figure 8b) ; however, it was not confirmed by a direct cell count using a hemocytometer. Purified b2m from human urine (Sigma Aldrich) in doses ranging from 100 to 800 ng ml -1 also did not affect proliferation of prostate and melanoma cells, independently of the status of b2m gene in the studied cells (some cell were b2m-positive and some b2m-deficient; Figure 8c ).
Analysis of apoptosis in tumor cell lines transduced with AdCMVb2m
Flow cytometry analysis with PE-conjugated Annexin-V and 7-AAD was used to examine the effect of AdCMVb2m infection on tumor cell apoptosis of ESTDAB-109 and DNR-DC-M010 melanoma cells at different MOIs: the optimal dose, and 8 or 15 times of the optimal dose. Cells were transduced with adenovirus vector and 48 h later cells were stained with PE-Annexin-V and 7-AAD. Simultaneous staining with PE-Annexin-V and 7-AAD non-vital dye makes it possible to distinguish between intact cells (stained negative for both Annexin V and 7-AAD), cells in early apoptosis (stained positive for PE-Annexin-V and negative for 7-AAD), and in late apoptosis or after cell death (stained positive for both and Annexin V and 7-AAD). b2m recovery on transduced cells was confirmed by FACS analysis using L-368 mAb (histograms on Figures 9a and b) . The percentage of apoptotic cells that bound PE-Annexin-V but excluded 7-AAD was determined in the b2m cell population to estimate fraction of b2m expressing cells (transduced cells) in early stages of apoptosis. In basal conditions, DNR-DC-M010 cells are b2m-negative, but after viral transduction (optimal MOI) a 72.1% of the cells became positive (Figure 9a , FACS histogram on the left). In control culture, 89.4% of untransduced DNR-DC-M010 cells were viable, 2.3% were in early apoptosis, and 4.8% were in late or final stages of apoptosis (Figure 9a1) . After viral transduction with AdCMVb2m at optimal MOI, these numbers practically did not change: 87.4% of the transduced cells at MOI of 15 were viable, 3% were in early apoptosis, 5.7% were in the late or final stages of apoptosis (Figure 9a2) . At a higher viral dose (15 Â optimal MOI), the percentage of b2m-positive cells increased to 86.5% (Figure 9a , FACS histogram), and the percentage of apoptotic cells did not change significantly (Figure 9a3 ). Similar results were obtained for ESTDAB-109 cell line (Figure 9b ) at its optimal MOI and at 8 Â of the optimal MOI. In control experiments, cells were infected with C5 and the percentage of dead cells was below 2% for DNR-DC-M010 at both MOIs, and close to 8% for ESTDAB-109 at optimal MOI, increasing to 15% at higher MOI.
DISCUSSION
The lack of tumor rejection is associated with multiple cancer immune escape mechanisms, including the loss or low expression of tumor HLA class I molecules. There is accumulating evidence suggesting that immunotherapy is effective in eliminating HLApositive tumor cells, while cells with loss or downregulation of HLA antigens escape therapy-induced immune attack and produce new distant tumor lesions. Therefore, corrections of antigen presentation in tumor cells may result in much higher success rates of cancer treatment. We have previously demonstrated that adenovirus coding for b2m constitutes a promising approach to restore normal HLA class I expression in b2m-negative tumor cells of different histological type.
26 b2m forms a complex with HLA heavy chain and it has an important role in tumor immunity. In this study, we extended the characterization of the viral vector and demonstrated that re-expression of b2m leads to upregulation of functional HLA class I complex on tumor cell surface, which is able to stimulate specific T-cell immunity against malignant cells without compromising the APM function. We have demonstrated that b2m-deficient tumor cells infected with the b2m-coding replication-deficient adenovirus (AdCMVb2m) recover normal HLA class I surface expression as measured by indirect fluorescence with mAb directed against b2m or HLA class I cell surface complex. Here we demonstrate that this positive expression could be detected 3 h after the viral infection and the percentage of infected cells and the expression levels were gradually increasing with the time of incubation reaching the maximum at 12 h after infection (Figure1). In addition, newly formed HLA complex remained stable after freezing and thawing the transduced cells, a method used by some authors to ensure the stability of transgene expression. 33, 34 Expression of the functional HLA class I complex on the cell surface requires coordinated participation of multiple proteins, which are part of APM, including TAP1/2, tapasin, calnexin, calreticulin, LMP2/7 and Erp57. They process HLA antigens in the ER, control correct folding of the heavy chain, its association with b2m and correct transport of this complex to the cell surface via Golgi apparatus. The proper assembly in the ER and later transport to the cell surface is critical for successful antigen presentation, determines the efficiency of peptide loading and T-cell stimulation. Immunocytochemistry and confocal analysis confirmed positive HLA class I expression on transduced tumor cells. In addition, intracellular colocalization of the re-expressed b2m, HLA heavy chain and APM molecules in the ER site indirectly verified the expected proper binding of the transgene and the heavy chain assisted by APM molecules, as well as transport of the complex to the cell surface.
Adenoviruses have been widely studied and used for gene therapy because their high transduction efficiency and their lack of integration into the host genome avoiding an increase in genomic instability that is a critical characteristic for cancer therapy. Therefore, adenoviral vectors coding for tumor-associated antigenic peptides have been generated and used to increase tumor cell immunogenicity in the past. However, detailed knowledge on their mechanism of action for antitumor efficacy is lacking. In particular, there is not much information regarding the effect of recombinant adenoviral vectors on the APM and HLA expression in tumor cells. There are several important issues that have to be addressed to make this type of gene delivery vehicle appropriate for HLA class I recuperation. This includes analysis of the possible influence of adenovirus on the HLA class I/heavy chain/b2m/peptide complex assembly and transport to the cell surface supported by the components of the APM. There is an accumulating evidence suggesting that the change in the expression of heavy and light chain of the HLA class I complex, as well as APM components happens in coordinated manner in some types of cancer, 35 although the exact mechanism is not known. However, other reports demonstrate that in some types of malignancy the regulation of locus-specific HLA and PC3 (a) were incubated for 72 h with supernatants from melanoma cells infected with the virus at different multiplicity of infection (MOI; optimal MOI, 10 Â and 20 Â ) and with control supernatants from non-transduced cells (cell proliferation was normalized against control proliferation value corresponding to cell incubated with a b2m-free supernatant from untransduced melanoma cells). *Po0.5; **Po0.05; ***Po0.005. transcription varies. Therefore, we examined how re-expression of b2m using adenoviral vector affects the mRNA levels of the HLA-A, B and C loci, as modulation of HLA heavy chain expression could potentially affect peptide presentation, their affinity and specificity of locus-specific peptide binding to HLA class I complex. The analysis of HLA-ABC locus transcription after b2m recovery showed locus B transcriptional upregulation and various patterns of locus A and C changes in different cell (Figure 3a) . Notably, locus B appeared to be more responsive to IFN-g stimulation, as well (Figures 3a and b) . Similar results were observed on protein level by analyzing locus-specific expression in transduced and permeabilized cells, namely, an upregulation of locus B without significant modulation of locus A (Figure 3b ). This finding is in accordance with previous description of differential expression of HLA class I loci after b2m plasmid transfection of HLA-Ideficient melanoma cell lines, 36 a phenotype that appears to be caused by abnormalities in regulatory mechanisms, since it can be recovered by IFN-g. Moreover, it has been also described that the three loci can be expressed at different levels in different types of tumor cells 37, 38 and in normal tissues 39 probably due to differences in the expression of regulatory factors that control HLA-ABC constitutive expression affecting the promoter region of the HLA heavy chain. 40, 41 Therefore, we cannot totally exclude a virus-induced modulation of HLA class I expression in tumor cells after recuperation of b2m expression. The observed increase in HLA-B expression after transduction with both Adb2m and c5 (stronger after control virus transduction) could be associated with intracellular anti-viral response.
There is a controversial data on how adenoviruses of different serotypes affect antigen processing and presentation. Some authors indicate that adenoviruses inhibit the intracellular transport of class I antigens and markedly reduce their cell surface expression. 42 Other reports show that Ad5-but not Ad12-transformed cells show variable but significant expression of class I H-2 antigens on mouse cells, 43 even increased levels of major histocompatibility complex class I expression 44 or the same level as untransformed Ad5 cells. 45 There have been different reports on the adenoviral-mediated modulation of the APM molecules in antigen-presenting cells, including tumor cells and DCs. Cells transformed by Ad5 but not Ad12 expressed either higher 46, 47 or normal 46,48 levels of TAP1/TAP2 and LMP2/LMP7 mRNAs; data from murine tumors injected with AdGFP vector show no alteration of the equivalent TAP1/TAP2 and LMP2/LMP7 mRNAs. 49 Adenoviral vectors have been used to restore TAP1 expression in tumor cells and tumor-specific immune response was stronger, while other APM molecules remained unchanged. 50, 51 Virusmediated transfer of calreticulin gene also increases specific antitumor immunity without modification of other APM components. 24 interfering with peptide loading, and as a result, blocks the association of TAP with tapasin and the transport process. 55, 25 However, some studies demonstrate that adenoviral vectors constructed without elimination of E3/19K do not always induce reduction of surface major histocompatibility complex class I expression in tumor cells. 56 In our case, AdCMVb2m is replication-deficient and lacks E3/19K gene. Thus, virus-mediated APM downregulation is not expected in tumor cells transduced with this virus.
On the other hand, other mechanisms may negatively affect antigen presentation by the viral vector. Therefore, we examined APM component expression in virally transduced tumor cells by quantitative PCR, immunocytochemical, confocal microscopy and FACS on permeabilized cells. All the results show that the adenoviral vector upregulates b2m and the cell surface HLA class I complex expression and does not inhibit antigen presentation, as the mRNA levels of the APM components as well as their protein expression are unchanged after viral infection. In addition, confocal microscopy data suggest that the intracellular trafficking and assembly of the b2m and HLA heavy chain with the support of AMP molecules takes place as expected, similar to other publications. [57] [58] [59] [60] The proper expression of the cell surface HLA class I complex results in the presentation of the tumor-associated peptide to the cytotoxic T cells and their activation. We observed that IFN-g secretion by T cells primed with b2m-negative melanoma cells was recovered after adenoviral transfer of wild-type b2m and recuperation of normal HLA class I expression. This stimulation of T cells by melanoma cells pulsed with melanoma-specific or flu peptide was observed only after transfer of wild-type b2m gene and recovery of HLA class I cell surface expression. Therefore, the recovery of HLA class I expression mediated by adenoviral b2m transfer induces stimulation of T cells, allowing the proper recognition of tumor-associated antigenic peptides by HLA class I-restricted CD8 þ T cells, a fundamental event for the detection and destruction of malignant cells.
The efficacy of gene therapy also depends on how the transgene affects target cells, how it influences cell viability and proliferation. We have demonstrated above that b2m protein produced after adenovirus-mediated gene transfer is properly expressed on tumor cell surface in a complex with HLA heavy chain. However, it is expected that in case of b2m overproduction the excess of the newly synthesized b2m will not have enough free heavy chains to form HLA class I complex with peptides and will be secreted into the extracellular space.
We found different levels of soluble b2m in the culture supernatant of AdCMVb2m-transduced tumor cells, ranging from 50 to 200 ng ml -1 at optimal MOI and reaching 2 mg ml -1 with 20 Â MOI. Physiological serum b2m concentrations vary from 1 to 3 mg ml -1 in physiological conditions and it increases up to 10-20 mg ml -1 in disease conditions. 61 Prostate cell line showed a minimal production of soluble b2m protein, while Burkitt lymphoma cell line DAUDI that did not recover cell surface b2m expression, 26 secreted soluble b2m protein. It could be explained by the data recently published suggesting that this cell line does not require b2m for cell surface expression of HLA heavy chains and peptide presentation. 62 Free soluble b2m is found in body fluids under physiological conditions as a result of shedding and extracellular release, or cell death in cancer or other diseases. Elevated levels of serum b2m correlate with poor prognosis in renal diseases and are present in hematological malignancies, including lymphomas, leukemias and multiple myeloma. This observation suggests an important, yet unidentified, role of this protein in these malignancies. In addition to the roles in immunity, the level of b2m is associated with proliferation, apoptosis and metastasis in several cancer types. Some studies have shown that increased concentration of soluble b2m protein is linked to increased tumor growth in various types of malignancy, including prostate, breast, lung and renal cancer. 63 Some publications demonstrate that b2m acts as a signaling and growth-promoting factor for prostate cancer and cancerassociated bone metastasis. 32, 64 However, there is evidence that b2m secreted in sera is modified by proteolytic cleavage 65 and this modified form can exert other biological functions.
As our in vitro experiments demonstrated that most of the studied cell lines after AdCMVb2m transduction not only recover cell surface expression of b2m/heavy chain complex, but also produce free soluble form of b2m protein, we decided to analyze how it affects tumor cell proliferation and apoptosis. We measured proliferation of prostate tumor cells DU-145 and PC3 incubated with b2m-rich supernatants collected after transduction of melanoma cells with various doses of the AdCMVb2m or with human b2m purified from urine and did not see any significant increase in the proliferation measured by MTT method or by direct cell counting, although in some cases MTT reading were slightly changed in the presence of the b2m-transduced melanoma cell supernatants.
In addition, viral proteins are capable of modulating the apoptotic response of host cells. Following the infection with human adenoviruses, cells exhibit an apoptotic response mediated by the expression of the viral E1A protein and adenoviral gene E6 products. On the other hand, E1B-19K blocks host cell apoptosis, and various proteins encoded by the E3 transcription unit. However, in this study neither replicationdeficient adenovirus coding for b2m nor control C5 virus induced apoptosis in infected tumor cells.
In summary, our data indicate that replication-deficient adenoviral vector coding for human b2m gene that had been generated to upregulate tumor HLA class I expression is suitable for gene therapy of cancer, as it effectively induces specific antitumor T-cell activity without inhibition of antigen processing and presentation or stimulation of tumor cell proliferation, or apoptosis. The AdCMVb2m would be suitable for patients with metastatic cancer with structural defects in b2m gene, where local administration of the vector into such metastatic lesions or into recurrent tumors may help to boost tumor cell immunogenicity and recognition by T cells, preventing malignant progression and improving the response to immunotherapy.
